26
total announcements
500124.BO · 15 min delayed
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd. has informed about the grant of employee stock options under the Employees Stock Option Scheme, 2018. The company has approved the grant of 15,933 stock options to eligible employees at a price of Rs. 1,206 per share, with 100% vesting at the end of 3 years.
Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Ltd has announced the appointment of Dr Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, effective July 22, 2026. The company has also appointed M/s Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm for a term of five consecutive years.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenues of Rs. 80,705 million, gross profit of Rs. 37,540 million, and a net profit of Rs. 4,348 million. The company has also announced the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and the appointment of M/s Deloitte Haskins & Sells, LLP as the Independent Registered Public Accounting Firm.
Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Ltd announced unaudited financial results for the quarter ended June 30, 2026, with revenues of Rs 80,705 million, gross profit of Rs 37,540 million, and profit for the period of Rs 4,348 million. The company also announced the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and the appointment of M/s Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd. announced that its Board of Directors will convene on July 22, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. In accordance with SEBI insider trading regulations, the trading window for the company's securities will be closed from June 24, 2026, until July 24, 2026. This closure is standard practice ahead of financial result announcements to prevent insider trading.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd. announced that its Board of Directors will convene on July 22, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This is a routine regulatory filing ahead of the quarterly earnings release. Concurrently, the trading window for the company's securities will remain closed from June 24, 2026, until July 24, 2026, for designated persons.